{"id":"placebo-obr","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T12:30:48.131707","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"In Phase 3 trials, placebo + active comparator arms serve as control groups to demonstrate that an investigational drug performs better than standard care or placebo alone. OBR likely refers to an existing standard-of-care treatment or active comparator. The placebo component isolates the effect of OBR and provides a baseline for assessing the investigational drug's true benefit.","oneSentence":"This is a placebo control arm combined with OBR (a comparator treatment), used in a Phase 3 clinical trial to establish efficacy and safety baselines.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:27:56.843Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["pubmed(11)"],"trialDetails":[{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT04159415","phase":"PHASE2","title":"Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-01-07","conditions":"Generalized Lipodystrophy","enrollment":16},{"nctId":"NCT05088460","phase":"PHASE2","title":"A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-02-28","conditions":"Familial Partial Lipodystrophy, Metabolic Abnormalities","enrollment":20},{"nctId":"NCT05327803","phase":"PHASE2, PHASE3","title":"Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease","status":"TERMINATED","sponsor":"AN2 Therapeutics, Inc","startDate":"2022-05-20","conditions":"MAC Lung Disease, Treatment Refractory MAC Lung Disease","enrollment":177},{"nctId":"NCT03287960","phase":"PHASE3","title":"Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity","status":"COMPLETED","sponsor":"Rhythm Pharmaceuticals, Inc.","startDate":"2018-01-30","conditions":"Leptin Receptor Deficiency Obesity","enrollment":15},{"nctId":"NCT04406727","phase":"PHASE3","title":"UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"United BioPharma","startDate":"2023-12-01","conditions":"HIV-1 Infection","enrollment":50},{"nctId":"NCT00685360","phase":"PHASE2","title":"A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-05-08","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis","enrollment":481},{"nctId":"NCT00515827","phase":"PHASE2","title":"Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-11","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT01424670","phase":"PHASE3","title":"Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-09-02","conditions":"Multidrug-resistant Tuberculosis","enrollment":511},{"nctId":"NCT01568892","phase":"PHASE3","title":"Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-04-18","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00352053","phase":"PHASE3","title":"Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-06","conditions":"HIV Infections","enrollment":87},{"nctId":"NCT00254046","phase":"PHASE3","title":"TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-11","conditions":"HIV","enrollment":616},{"nctId":"NCT00255099","phase":"PHASE3","title":"TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-12","conditions":"HIV","enrollment":593}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo + OBR","genericName":"Placebo + OBR","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}